Stellaromics Announces Installation of First Pyxa™ 3D Spatial Transcriptomics System at the University of Glasgow

Milestone Marks the Launch of External Beta Testing for Groundbreaking 3D Spatial Multi-Omics Platform

BOSTON, Oct. 14, 2025 /PRNewswire/ -- Stellaromics, a pioneer in 3D spatial biology, today announces the installation of the first Pyxa™ instrument at the University of Glasgow in the laboratory of Dr. Nigel Jamieson, Professor of Hepatobiliary and Pancreatic Surgery in the School of Cancer Sciences and Group Leader of the Jamieson Spatial Laboratory. This key achievement initiates the external beta testing program for the Pyxa system and represents a major milestone in the commercialization of Stellaromics' foundational technology.

Dr. Jamieson's team will focus on deploying the Pyxa system to dissect the intricate cellular landscapes of cancer, specifically the dynamics of invasion within the tumor microenvironment.

"Pyxa has the potential to fundamentally transform how we study the complex microenvironment of cancer. By combining spatial resolution with single-cell precision, Pyxa opens a new window into how tumors interact, co-opt and invade their surrounding tissues, blood vessels and nerves. With this technology, we are excited to map the physical organization of tissue interfaces, assign precise single-cell phenotypes, and investigate multi-cellular communities and niches in three dimensions. We believe this approach will overcome longstanding challenges in capturing tissue morphology and avoiding cellular misassignment, particularly within the intense environment of tumors including glioblastoma, pancreatic cancer, and colorectal cancer as they invade healthy tissue," said Jamieson.

In addition to supporting his own research, Dr. Jamieson's laboratory serves as a spatial biology core facility, with plans to collaborate broadly across diverse sample types to demonstrate the unique capabilities of the Pyxa system and the transformative potential of 3D spatial transcriptomics.

"We look forward to deploying this powerful tool in patient-derived samples and models to better understand the dynamic nature of cancer," Jamieson added.

Designed to deliver high-resolution, multiplexed 3D spatial transcriptomics in intact tissue sections up to 100 µm thick, Pyxa overcomes inherent limitations of conventional 2D thin section approaches by preserving native tissue architecture and spatial context across multiple cellular layers. The system captures subcellular detail for hundreds of molecular targets simultaneously, enabling researchers to resolve complex tissue organization, characterize cell–cell interactions, and map molecular gradients that underpin biological processes in health and disease.

"The installation of the first external Pyxa system is a landmark event for Stellaromics and a critical step in bringing true 3D spatial biology to the global research community," said Todd Dickinson, PhD, CEO of Stellaromics. "Dr. Jamieson and his team are true innovators in spatial biology, and their role as a spatial biology core facility makes them an ideal partner to validate the unique applications of Pyxa across a broad range of disease areas. This partnership accelerates our mission to commercialize a system that will unlock unprecedented insights into complex tissue architecture, starting with the tumor microenvironment."

With additional beta installations planned at leading academic and research institutions in the coming months, Stellaromics is transforming how biology is studied — moving beyond flat, two-dimensional snapshots to reveal the true three-dimensional complexity of tissue biology. Stellaromics will showcase the Pyxa platform and its transformative 3D spatial biology capabilities at the upcoming American Society of Human Genetics (ASHG) Annual MeetinginBoston, October 14-18, 2025.

About Stellaromics

Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company's mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health. Stellaromics is headquartered in Boston, Massachusetts, USA.

Media Contact
Kristen White
Co-Founder & Partner, Oak Street Communications
[email protected]
415.608.6060

SOURCE Stellaromics